JP2022537964A5 - - Google Patents

Info

Publication number
JP2022537964A5
JP2022537964A5 JP2021574283A JP2021574283A JP2022537964A5 JP 2022537964 A5 JP2022537964 A5 JP 2022537964A5 JP 2021574283 A JP2021574283 A JP 2021574283A JP 2021574283 A JP2021574283 A JP 2021574283A JP 2022537964 A5 JP2022537964 A5 JP 2022537964A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
stereoisomer
acceptable salt
compound according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021574283A
Other languages
English (en)
Japanese (ja)
Other versions
JP7657740B2 (ja
JP2022537964A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037853 external-priority patent/WO2020257145A1/en
Publication of JP2022537964A publication Critical patent/JP2022537964A/ja
Publication of JP2022537964A5 publication Critical patent/JP2022537964A5/ja
Application granted granted Critical
Publication of JP7657740B2 publication Critical patent/JP7657740B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021574283A 2019-06-18 2020-06-16 Jakキナーゼのピラゾロピリミジンスルホン阻害剤およびその使用 Active JP7657740B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/091712 2019-06-18
CN2019091712 2019-06-18
US202063035381P 2020-06-05 2020-06-05
US63/035,381 2020-06-05
PCT/US2020/037853 WO2020257145A1 (en) 2019-06-18 2020-06-16 Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof

Publications (3)

Publication Number Publication Date
JP2022537964A JP2022537964A (ja) 2022-08-31
JP2022537964A5 true JP2022537964A5 (cg-RX-API-DMAC7.html) 2023-06-22
JP7657740B2 JP7657740B2 (ja) 2025-04-07

Family

ID=71575774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021574283A Active JP7657740B2 (ja) 2019-06-18 2020-06-16 Jakキナーゼのピラゾロピリミジンスルホン阻害剤およびその使用

Country Status (18)

Country Link
US (2) US11453671B2 (cg-RX-API-DMAC7.html)
EP (1) EP3986901A1 (cg-RX-API-DMAC7.html)
JP (1) JP7657740B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220024405A (cg-RX-API-DMAC7.html)
CN (1) CN114008051B (cg-RX-API-DMAC7.html)
AU (1) AU2020297415A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025618A2 (cg-RX-API-DMAC7.html)
CA (1) CA3140024A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003341A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000118A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210661A (cg-RX-API-DMAC7.html)
IL (1) IL288957A (cg-RX-API-DMAC7.html)
MA (1) MA56518A (cg-RX-API-DMAC7.html)
MX (1) MX2021015319A (cg-RX-API-DMAC7.html)
PE (1) PE20220577A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552998A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115068A (cg-RX-API-DMAC7.html)
WO (1) WO2020257145A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114026096B (zh) 2019-06-18 2025-02-07 豪夫迈·罗氏有限公司 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途
KR102767443B1 (ko) * 2022-04-14 2025-02-12 한국화학연구원 퀴녹살린 카르복스아마이드 유도체 및 이를 유효성분으로 포함하는 교모세포종의 예방 또는 치료용 약학적 조성물
EP4522598A1 (en) 2022-05-11 2025-03-19 PI Industries Ltd. Bicyclic compounds and their use as pest control agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH11508583A (ja) 1995-07-06 1999-07-27 ゼネカ・リミテッド ペプチド系のフィブロネクチン阻害薬
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
AU2002361992A1 (en) 2001-12-20 2003-07-09 Bayer Aktiengesellschaft 1,4-dihydro-1,4-diphenylpyridine derivatives
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
CN101616921A (zh) * 2007-01-30 2009-12-30 比奥根艾迪克Ma公司 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途
AU2008211172A1 (en) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. 1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases
AU2009259853A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine JAK inhibitor compounds and methods
BRPI0914404A2 (pt) 2008-10-31 2019-03-06 Genentech Inc "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente"
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
HUE047441T2 (hu) 2012-11-09 2020-04-28 Medicines For Malaria Venture Mmv Heteroaril-származékok és alkamazásaik
HRP20210935T1 (hr) 2014-05-23 2021-08-06 F. Hoffmann - La Roche Ag Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
WO2017140825A1 (en) 2016-02-18 2017-08-24 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof
MX2019007339A (es) 2016-12-29 2019-09-06 Hoffmann La Roche Compuestos de pirazolopirimidina y metodos de uso de los mismos.
JP2020510061A (ja) 2017-03-14 2020-04-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ピラゾロクロロフェニル化合物、組成物及びその使用方法
WO2018215390A1 (en) * 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
JP7256757B2 (ja) 2017-05-22 2023-04-12 エフ. ホフマン-ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
WO2019139714A1 (en) * 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
CA3127701C (en) * 2019-01-25 2023-08-15 Beijing Scitech-Mq Pharmaceuticals Limited Acylamino bridged heterocyclic compound, and composition and application thereof
CN114026096B (zh) 2019-06-18 2025-02-07 豪夫迈·罗氏有限公司 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途
EP3986899A1 (en) 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof

Similar Documents

Publication Publication Date Title
CN1360499A (zh) 含有非诺贝特的药物组合物及其制备方法
CN1080120C (zh) 药物组合物
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
JP2023549226A5 (cg-RX-API-DMAC7.html)
JP2014523445A5 (cg-RX-API-DMAC7.html)
JP2019510787A5 (cg-RX-API-DMAC7.html)
JP2000500469A (ja) 抗ニューモシスティス属作用物質としてのベンズアミドオキシム系プロドラッグ
JPH07501539A (ja) N,n’−ジアセチルシスチンの有機塩
JP2022507251A (ja) P2x3調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用
JP2023076632A5 (cg-RX-API-DMAC7.html)
US7208598B2 (en) Derivatives of purine, their preparation process and pharmaceutical compositions containing them
CN108358917B (zh) 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法
JP2022527401A5 (cg-RX-API-DMAC7.html)
JP2018537513A5 (cg-RX-API-DMAC7.html)
JP2019530674A5 (cg-RX-API-DMAC7.html)
JP2020533296A5 (cg-RX-API-DMAC7.html)
Durham et al. Spray dried aerosol particles of pyrazinoic acid salts for tuberculosis therapy
JP2023512664A5 (cg-RX-API-DMAC7.html)
JP2023551467A (ja) 5’-o-フェニルアセチルウリジン及び治療上の使用
Hegde et al. Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS)
Ueda et al. Improvement in inhalation properties of theophylline and levofloxacin by co-amorphization and enhancement in its stability by addition of amino acid as a third component
CN104546819A (zh) 二咖啡酰奎宁酸在治疗系统性自身免疫性疾病中的用途
CN116437929A (zh) 抗微生物化合物的吸入制剂
JP2018521001A (ja) 化合物 (s)−3−{4−[5−(2−シクロペンチル−6−メトキシ−ピリジン−4−イル)−[1,2,4]オキサジアゾール−3−イル]−2−エチル−6−メチル−フェノキシ}−プロパン−1,2−ジオールの結晶形
WO2012110462A1 (en) Liquid propellant-free formulation comprising an antimuscarinic drug